The shift in 2026 pharmacy benefits, driven by reforms under the Consolidated Appropriations Act, is tightening oversight on Pharmacy Benefit Managers (PBMs) through stronger transparency requirements, rebate reporting, and fiduciary accountability, directly impacting how contracts, pricing models, and reimbursement structures are managed.
For 340B stakeholders operating under the 340B Drug Pricing Program, the changes increase compliance monitoring, audit risk, and data tracking obligations to prevent duplicate discounts and ensure accurate claims validation. As a result, both PBMs and 340B covered entities must strengthen compliance systems, contract oversight, and real-time monitoring to maintain financial stability and regulatory alignment in 2026 and beyond.
![340B Drug Pricing Program](\"https://northarc.server2.purelogics.net/wp-content/uploads/2025/12/ChatGPT_Image_Dec_17_2025_07_04_53_PM-1-2.png\"){kind=link}
What the CAA Means for PBMs and 340B Operations
The pharmaceutical supply chain is changing faster than ever. On February 3, 2026, the Consolidated Appropriations Act (CAA) of 2026 became law. If you are a plan fiduciary, a retail pharmacy director, or managing a Covered Entity, you already know the old ways of doing business are over.
The federal government has initiated a massive overhaul of how drug pricing and pharmacy benefit managers (PBMs) operate. The goal? Moving away from volume-based incentives and hidden margins toward a transparent, fee-for-service model. We now have a 30-month window to get operations ready.
Identifying the Major Stakeholders
Pharmacy Benefit Managers (PBMs)
PBMs act as intermediaries between health plans, pharmacies, and manufacturers, managing formularies and claims processing. They negotiate manufacturer rebates and have historically earned revenue through spread pricing and rebate retention. Their decisions influence employer-sponsored plans and Medicare Part D, impacting drug costs and patient access.
340B Drug Pricing Program
The 340B program helps safety-net providers access outpatient drugs at discounted prices from manufacturers. These discounts fund uncompensated care, community services, and hospital programs. Covered entities must track inventory and claims carefully to prevent compliance violations and ensure proper use of funds.
The Big Shift: 100% Pass-Through and Flat Fees
The most impactful change in CAA 2026 is the absolute requirement for PBMs to remit 100 percent of all manufacturer-derived funds directly to the plan sponsor. This fundamentally breaks the traditional “black box” revenue model. PBMs can no longer negotiate discounts and retain a large percentage.
How the New Rules Will Work (Starting Late 2028 / Early 2029)
- Quarterly Liquidity
PBMs must legally pass through all manufacturer-derived funds every quarter, ensuring faster liquidity for plan sponsors. - The Rise of Bona Fide Service Fees (BFSF)
PBMs must pivot to a flat-fee compensation structure based strictly on services performed. - No More Volume Incentives
These Bona Fide Service Fees cannot vary based on drug price or formulary placement.
This aligns incentives across stakeholders. PBM compensation is now tied to clinical appropriateness and administrative performance, not the price of a specialty drug.
The Transparency Mandate: Fiduciary Risks are Real
With the new financial structure comes intense reporting requirements. PBMs must now provide detailed, drug-level data to plan sponsors. However, this transparency creates new exposure.
Because the law mandates verification tool sets, plan fiduciaries who fail to audit their PBMs could face liability. Industry experts are already predicting increased ERISA litigation.You have the statutory right to audit your PBM. Use it.
The Medicare Part D Reality Check: Split Reimbursements
On January 1, 2026, the first ten drugs selected for Medicare price negotiations reached the pharmacy counter with Maximum Fair Prices (MFP). If you manage a retail pharmacy, you know this wasn’t just a pricing change it was a massive workflow headache.
When dispensing an MFP drug, reimbursement is now split:
- Target: The PBM reimburses you at the negotiated MFP ceiling price.
- Target: The drug manufacturer owes you the difference between the MFP and the Wholesale Acquisition Cost (WAC).
This dual-stream model means longer reconciliation cycles and complex accounts receivable. Manufacturer refunds simply don’t follow the same clean, bi-weekly cycle as PBM claims. Your back office is going to feel this squeeze.
A Win for 340B: Upfront Discounts Remain Safe
In early 2026, we saw the official defeat of the highly controversial HRSA 340B pilot program.This pilot would have shifted the 340B drug pricing program away from upfront discounts toward a post-sale model. Following successful legal challenges from hospital coalitions who argued this would devastate safety-net providers, HHS agreed to scrap the program in February.
The takeaway: The “upfront discount” model that hospitals desperately rely on to fund care for vulnerable communities is safe.
State Mandates Are Moving Faster Than Federal Reform
While the federal CAA 2026 set a national floor for transparency, individual states are moving aggressively often ahead of the federal timeline.
- Florida, Idaho, and Alabama have already implemented bans on spread pricing and mandated 100% pass-throughs.
- Arkansas pushed hard against vertical integration, attempting to ban PBMs from forcing patients to use PBM-owned pharmacies (though this is currently tied up in federal appeals).
These state-level successes prove one thing: transparency directly translates into premium reductions.
The Tech Imperative: AI and Compliance Automation
By late 2026, the sheer volume of compliance data and regulatory reporting will bury lean teams. You cannot hire your way out of this.
Compliance automation has shifted from “nice-to-have” to a basic operational necessity. We are seeing organizations successfully deploy AI-powered reporting pipelines to: Ingest data and generate real-time risk assessments.
- Provide clear audit trails for plan fiduciaries.
- Reduce routine compliance labor costs by 30-50%.
However, patient safety and privacy remain paramount. “Near-live access logs” are now standard, and licensed pharmacists must always provide a “human-in-the-loop” review of any algorithmic recommendations.
Operational Impacts on PBMs
1. Transition from Margin-Based Revenue to Service-Based Revenue
PBMs are moving away from earning profits through spread pricing and retained rebates. Instead, they are adopting a service-fee model tied to administrative or clinical functions. This shift requires new contracts, operational efficiency, and investment in technology to justify fees.
2. Increased Audit Exposure
Plan fiduciaries now have stronger rights to audit PBMs, reviewing every transaction and rebate allocation. PBMs must maintain detailed records and robust compliance frameworks. Noncompliance can lead to financial penalties or ERISA-related litigation.
3. More Stringent Reporting Obligations
PBMs must provide drug-level transparency to plan sponsors, including costs, utilization, and rebates. This requires advanced reporting tools and secure data systems. Accurate, timely reporting ensures compliance and builds trust with clients.
4. Reduced Flexibility in Rebate Structuring
PBMs can no longer retain rebates as discretionary revenue. Rebates must primarily benefit plan sponsors or patients, limiting profit opportunities. PBMs must adjust contract negotiations and formulary strategies to remain competitive.
5. Shift Toward Transparent Service Vendors
PBMs are evolving from profit-focused intermediaries into service-oriented providers. They now deliver value through clinical management, administrative efficiency, and data insights. This aligns their incentives with plan sponsors and patient outcomes rather than hidden margins.
Operational Impacts on 340B Entities
1. Increased Scrutiny from Manufacturers and Regulators
340B covered entities are under closer observation from both drug manufacturers and federal regulators. Manufacturers are reviewing claims and purchase patterns more rigorously to ensure compliance with 340B eligibility rules. Regulatory agencies are also increasing oversight and audits, which can affect pricing, reimbursement, and operational practices.
2. Heightened Compliance Documentation Requirements
Entities must maintain detailed records of 340B drug purchases, patient eligibility, and dispensing logs. This ensures that every claim can be verified during audits. Operationally, organizations need robust data systems and staff training to manage documentation without disrupting patient care.
3. Pressure to Strengthen Internal Controls
The risk of audit findings or compliance violations is rising, so entities must enhance internal controls over inventory management, contract pharmacy operations, and billing processes. Implementing checks and balances reduces the chance of errors and demonstrates due diligence to regulators and manufacturers.
4. Greater Complexity in Contract Pharmacy Relationships
As contract pharmacies participate more in 340B programs, covered entities must carefully monitor dispensing practices, pricing, and compliance. Operationally, this requires formal agreements, real-time reporting, and oversight mechanisms to avoid duplicate discounts or program misuse.
5. Audit-Ready Operations at All Times
Given the increased scrutiny and complex rules, 340B entities must maintain constant readiness for audits. This means having accurate records, proper inventory tracking, and clear compliance processes. Being audit-ready reduces risk of penalties and protects the organization’s 340B benefits.
Moving Forward: How NorthArc Can Help
The 2026 transparency mandates mark the end of an era defined by “mystery and margin.” PBMs are transitioning from price arbitrageurs strictly to essential service providers. NorthArc is helping organizations navigate this transition with clarity and precision.
Navigating Complex Reimbursement and Audit Requirements
With split-reimbursement flows and increased audit responsibilities, staying compliant demands a robust operating system. Teams must adapt to avoid errors and ensure smooth operations.
Why Lean Teams Don’t Need Massive Software Platforms
If your team is lean and operational noise is overwhelming, you don’t necessarily need a large new software platform. Instead, practical, repeatable controls can streamline workflows effectively.
Selective Ops Support: Your Operational Extension
Our Selective Ops Support functions as an extension of your staff. We integrate with your TPA and internal processes to establish audit-ready practices, catch exception errors, and prevent revenue leakage.
Act Before the 30-Month Window Closes
The 30-month operational window is limited. Early adoption of structured support ensures your team remains compliant, efficient, and financially secure.
Conclusion
The 2026 pharmacy benefit reforms are a major shift impacting PBMs, 340B entities, and plan fiduciaries. PBMs must adopt transparent, service-based models to sustain revenue and build trust. 340B entities need stronger compliance systems and audit readiness to avoid penalties.
Plan fiduciaries must actively verify pass-throughs to ensure proper oversight. Organizations that adapt early will gain operational clarity, financial stability, and strategic advantage.